Microfluidic Microdroplet Assay for Rapid Antimicrobial Testing

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for rapid and accurate profiling of infection-causing organisms and antimicrobial sensitivities are inadequate, particularly in clinical settings, as they are slow, cumbersome, and lack the ability to perform simultaneous multiplexed assays on multiple medicaments and cells.

Innovation Solution

A method involving the creation of arrays of microdroplets containing cells and medicaments at varying concentrations, merged on a microfluidic chip using electrowetting technology, allowing for optical detection of interactions and determination of minimum inhibitory concentrations (MIC) using an optical detection system.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If continuous flow microfluidics is used for MIC determination, then the method is simple and fast, but the ability to perform broad multiplexed assays with multiple medicaments and concentrations is limited

Engineering Contradiction:
Improvethroughput of multiplexed assaysVSAvoidcomplexity of microfluidic platform
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The system segments the assay into distinct functional zones within the microfluidic device: a loading zone for sample introduction, a sorting zone for separating cell-containing droplets from empty droplets, and an analysis zone for optical detection. This segmentation enables complex multiplexed assays to be performed through a relatively simple linear device architecture, resolving the contradiction between throughput and device complexity.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention transitions from two-dimensional planar assays to three-dimensional droplet-based assays, where multiple medicaments and concentrations can be tested simultaneously in parallel droplets. This dimensional change enables broad multiplexed assays without proportionally increasing device complexity, as the multiplexing is achieved through the third dimension of droplet suspension and manipulation.

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

2Adaptability or versatility

If microdroplet manipulation platforms are used to enable broad multiplexed assays, then assay versatility is improved, but the throughput is limited due to inability to discard empty droplets

Engineering Contradiction:
Improvepanel of tests capabilityVSAvoidthroughput of cell-containing droplets
Core Design Contradiction:
Adaptability or versatilityVSProductivity

Solution Approach 1:

The system extracts and removes empty droplets from the flow stream in the sorting zone, separating them from cell-containing droplets. This extraction of unwanted empty droplets prevents them from clogging the system or interfering with subsequent analysis, thereby maintaining high throughput while enabling versatile multiplexed assays. The sorting is achieved through optical detection and targeted manipulation.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The microfluidic device introduces an intermediary sorting mechanism between droplet generation and final analysis. This intermediary sorting zone uses optical detection and controlled manipulation to identify and separate empty droplets from cell-containing droplets, enabling the system to maintain both high versatility in assay panels and high throughput by preventing empty droplet accumulation.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Measurement precision

If blood culture analysis is used as gold standard for infection diagnosis, then diagnostic accuracy is improved, but the method is too slow to influence initial patient management

Engineering Contradiction:
Improvediagnostic accuracyVSAvoidtime to obtain results
Core Design Contradiction:
Measurement precisionVSLoss of time

Solution Approach 1:

The system performs preliminary actions by rapidly preprocessing and sorting droplets immediately after sample introduction, identifying cell-containing droplets early in the workflow. This preliminary sorting and detection enables faster turnaround time while maintaining diagnostic accuracy, as the system begins analysis immediately rather than waiting for traditional culture methods to complete their full incubation period.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The invention skips the lengthy traditional culture incubation period by using rapid optical detection methods that can identify and characterize cells within minutes rather than days. The system rushes through the diagnostic process by performing real-time monitoring and analysis of droplet contents, enabling fast turnaround time while preserving measurement precision through advanced optical detection techniques.

Inventive Principle:
Principle #21Skipping (Rushing through)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables quick and accurate characterization of antimicrobial resistance properties, facilitating effective treatment regimes by efficiently sorting viable cells, manipulating microdroplets, and monitoring cell behavior to determine MIC, thereby improving clinical diagnostic capabilities.

Implementation Method 1

loading the first microdroplets onto a microfluidic chip configured to manipulate the microdroplets using real or virtual electrowetting electrodes

Methodology Applied
Scientific EffectElectrowetting: Electrowetting

Implementation Method 2

monitoring the characteristics of one or more cells in the merged microdroplets using an optical detection system to detect an interaction between a cell type and a medicament

Methodology Applied
Scientific EffectOptical detection:

Data Source

PatentUS20230134003A1Method and apparatus for clinical testing
Publication Date: 2023.05.04 LIGHTCAST DISCOVERY LTD
  • US20230134003A1 patent drawing
  • US20230134003A1 patent drawing
  • US20230134003A1 patent drawing

AI summary

A method for determining an interaction between a medicament and a cell type comprising an array of first microdroplets, each containing a cell type derived from a biological sample, an array of second microdroplets, each containing one or more medicaments at one or more predetermined concentrations, merging the array of first microdroplets and the array of second microdroplets to form an array of merged microdroplets, and monitoring the characteristics of one or more cells in the merged microdroplets using an optical detection system configured to detect an interaction between a cell type and a medicament.